ArticleBMC pulmonary medicine2026
MiR-128-3p serves as a diagnostic biomarker in pediatric Mycoplasma pneumoniae pneumonia.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMycoplasma pneumoniae pneumonia (MPP) is a frequent pulmonary infection in children, and severe cases are associated with significant adverse outcomes. PURPOSE: To investigate the expression, clinical value, and functional mechanism of miR-128-3p in MPP.
methodsSerum samples from children with MPP were collected to measure miR-128-3p expression. ROC curve and logistic analysis were further performed to evaluate the clinical value of miR-128-3p in MPP. An MPP model was established by infecting BEAS-2B cells with Mycoplasma pneumoniae (MP). The functions of miR-128-3p were verified using CCK-8 and ELISA. Potential downstream target genes were predicted and verified by bioinformatics analysis and the dual-luciferase reporter assay.
resultsMiR-128-3p was significantly downregulated in the serum of children with MPP and served as an independent predictor of severe MPP (SMPP). Overexpression of miR-128-3p inhibited the secretion of IL-6, IL-8, and TNF-α and alleviated cell injury. ITGA5 is a target gene of miR-128-3p, which was upregulated in MPP. Rescue experiments verified that overexpression of ITGA5 abolished the anti‑inflammatory and protective effects of miR‑128‑3p.
conclusionMiR-128-3p is downregulated in MPP and serves as a predictive biomarker for SMPP, which exerts a protective effect by suppressing inflammatory responses.
Indexed as
Identifiers
42855679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.